Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of ¹⁷⁷ Lu-PSMA-617 radioligand-therapy in prostate cancer.

Autor: Fernández Calvo O; Department of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. ovidiofernandezcalvo@yahoo.es., Muñoz Iglesias J; Department of Nuclear Medicine (SERGAS), University Hospital of Vigo, Meixoeiro Hospital, Vigo, Spain., Abou Jokh Casas E; Department of Nuclear Medicine, Hospital Universitario Lucus Augusti, Lugo, Spain., Molina-Díaz A; Department of Medical Oncology, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain., Anido Herranz U; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Casas Nebra J; Uro-Oncology Unit, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain., García-Bernardo L; Department of Nuclear Medicine, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Martínez-Breijo S; Department of Urology, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain., Lázaro-Quintela M; Department of Medical Oncology, University Hospital of Vigo, Meixoeiro Hospital, Vigo, Spain., Muñiz-García G; Department of Nuclear Medicine, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Vázquez-Estevez S; Department of Medical Oncology, Hospital Universitario Lucus Augusti de Lugo, Lugo, Spain.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Sep 12. Date of Electronic Publication: 2024 Sep 12.

Drug cost avoidance in prostate cancer clinical trials

Autor: Calvin-Lamas, M., Portela-Pereira, P., Rabuñal-Alvarez, M.T., Martinez-Breijo, S., Martín-Herranz, M.I., Gómez-Veiga, F.

Publikováno v: In Actas Urológicas Españolas (English Edition) November 2015 39(9):553-557

Focal therapy for prostate cancer. Alternative treatment

Autor: Gómez-Veiga, F., Martínez-Breijo, S., Solsona-Narbón, E., Hernández, C., Ciudin, A., Ribal, M.J., Dickinson, L., Moore, C., Ahmed, H., Rodríguez Antolín, A., Breda, A., Gaya, J., Portela-Pereira, P., Emberton, M.

Publikováno v: In Actas Urológicas Españolas (English Edition) September 2014 38(7):465-475

Programa de monitorización de la vigilancia activa en cáncer de próstata en España de la Sociedad Española de Urología; resultados preliminares

Autor: Rubio-Briones, J., Borque, A., Esteban, L.M., Iborra, I., López, P.A., Gil, J.M., Pallás, Y., Fumadó, Ll., Martínez-Breijo, S., Chantada, V., Gómez, E., Quicios, C., Congregado, C.B., Medina, R., Ortiz, M., Montesino, M., Clar, F., Soto, J., Campá, J.M.

Publikováno v: In Actas Urologicas Espanolas January-February 2016 40(1):3-10

MicroARN circulantes en sangre de pacientes con cáncer de próstata

Autor: Medina-Villaamil, V., Martínez-Breijo, S., Portela-Pereira, P., Quindós-Varela, M., Santamarina-Caínzos, I., Antón-Aparicio, L.M., Gómez-Veiga, F.

Publikováno v: In Actas Urologicas Espanolas December 2014 38(10):633-639